Search - tctmd.com

Displaying 581 - 600 of 673

Sort: Relevancy | Date

News Daily News

Apixaban Reduce el Índice de Hospitalizaciones compardo con la Aspirina en Pacientes con Fibrilación Auricular

Jason Kahn

August 05, 2013

News Daily News

Apixaban Lowers Hospitalization Rate vs. Aspirin in A-fib Patients

Jason Kahn

August 05, 2013

Presentation

The Effects of Apixaban on Hospitalizations in Patients With Different Types of Atrial Fibrillation

Presenter: Stefan H. Hohnloser

August 01, 2013

News Daily News

轻微卒中/短暂性脑缺血发作后，双联抗血小板疗法与阿司匹林相比能够减少卒中复发

July 24, 2013

Presentation

Use and Associated Risks of Concomitant Aspirin with Oral Anticoagulation in A-fib Patients

Presenter: B. A. Steinberg

July 24, 2013

News Daily News

Después de un accidente cerebrovascular menor/AIT, la terapia antiplaquetaria doble reduce el accidente cerebrovascular recurrente en comparación con la aspirina

July 24, 2013

News Daily News

After Minor Stroke/TIA, Dual Antiplatelet Therapy Reduces Recurrent Stroke vs. Aspirin

July 24, 2013

News Daily News

Una Revisión de JAMA Aborda las Complejidades del Tratamiento Médico tras una PCI

Caitlin E. Cox

July 11, 2013

News Daily News

JAMA Review Tackles Intricacies of Medical Therapy After PCI

Caitlin E. Cox

July 11, 2013

Presentation

Clopidogrel with Aspirin in Acute Minor Stroke or TIA

Presenter: Yongjun Wang

June 26, 2013

News Daily News

Un Registro Danés Sugiere que la Aspirina No es Necesaria en Pacientes con FA tras un IM o PCI

Caitlin E. Cox

June 20, 2013

News Daily News

Danish Registry Suggests Aspirin Unnecessary in A-fib Patients After MI or PCI

Caitlin E. Cox

June 20, 2013

Presentation EuroPCR 2013

The Unplanned DAPT Discontinuation Patient: How Can I Make Informed Decisions?

Presenter: Sigmund Silber

May 22, 2013

Presentation

Clinical Outcome Following Discontinuation of DAPT After 12 months in Real-World Patients Treated with Second-Generation ZES and EES

Presenter: K. Tandjung

April 26, 2013

Presentation TCTAP 2013

The Future Is: New Antiplatelet Agents, Selective Platelet Function Testing, and Patient-Specific DAPT Duration

Presenter: Matthew J. Price

April 24, 2013

Presentation TCTAP 2013

Counterpoint: The Incremental Benefit Is Small and the Cost-Disadvantages of New DAPT Approaches Are Prohibitive

Presenter: Adnan Kastrati

April 24, 2013

News Daily News

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Caitlin E. Cox

April 19, 2013

News Daily News

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Caitlin E. Cox

April 19, 2013

Presentation

Decision Dilemmas in Adjunctive Pharmacology Choices in PCI Patients

Presenter: Roxana Mehran

April 15, 2013

Presentation

Nuisance Bleeding with Prolonged Dual Antiplatelet Therapy After AMI and Its Impact on Health Status

Presenter: A. P. Amin

March 26, 2013

Advertisement

Apixaban Reduce el Índice de Hospitalizaciones compardo con la Aspirina en Pacientes con Fibrilación Auricular

Apixaban Lowers Hospitalization Rate vs. Aspirin in A-fib Patients

The Effects of Apixaban on Hospitalizations in Patients With Different Types of Atrial Fibrillation

轻微卒中/短暂性脑缺血发作后，双联抗血小板疗法与阿司匹林相比能够减少卒中复发

Use and Associated Risks of Concomitant Aspirin with Oral Anticoagulation in A-fib Patients

Después de un accidente cerebrovascular menor/AIT, la terapia antiplaquetaria doble reduce el accidente cerebrovascular recurrente en comparación con la aspirina

After Minor Stroke/TIA, Dual Antiplatelet Therapy Reduces Recurrent Stroke vs. Aspirin

Una Revisión de JAMA Aborda las Complejidades del Tratamiento Médico tras una PCI

JAMA Review Tackles Intricacies of Medical Therapy After PCI

Clopidogrel with Aspirin in Acute Minor Stroke or TIA

Un Registro Danés Sugiere que la Aspirina No es Necesaria en Pacientes con FA tras un IM o PCI

Danish Registry Suggests Aspirin Unnecessary in A-fib Patients After MI or PCI

The Unplanned DAPT Discontinuation Patient: How Can I Make Informed Decisions?

Clinical Outcome Following Discontinuation of DAPT After 12 months in Real-World Patients Treated with Second-Generation ZES and EES

The Future Is: New Antiplatelet Agents, Selective Platelet Function Testing, and Patient-Specific DAPT Duration

Counterpoint: The Incremental Benefit Is Small and the Cost-Disadvantages of New DAPT Approaches Are Prohibitive

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Decision Dilemmas in Adjunctive Pharmacology Choices in PCI Patients

Nuisance Bleeding with Prolonged Dual Antiplatelet Therapy After AMI and Its Impact on Health Status

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content